

28 LUGLIO 2017

COMUNICATO STAMPA**MEDASYS ACQUISISCE NETIKA****Medasys Group announces the acquisition of Netika SAS**

Clamart, July 28th, 2017 – Medasys, major French publisher of medical software for public and private healthcare institutions in the fields of patient records, care production and technical platforms (biology, radiology, pharmacy), announces the acquisition of NETIKA SAS (joint-stock company), a company specializing in the development and commercialization of software dedicated to Quality Insurance Management and Laboratory Information System.

Presentation of Netika and expected synergies

With over 2,800 institutions using its solutions and a team of nearly 70 persons, Netika, a company based in Strasbourg (France) is a major player in the sector of Public and Private Laboratory Information Systems. Netika achieved a turnover of € 6.1 million in 2016 for an EBITDA of € 1 million. Its range of interconnected and multi-site solutions consists of a Quality Insurance Management tool (KaliLab) and a Laboratory Information System (KaliSil). Netika's softwares enrich Medasys' range of products and enable the publisher to offer new, modular solutions to its current clients.

The evolution of its offer and the biology department, now composed of more than 100 people, will enable Medasys Group to increase its presence in the private sector and provide a complete and appropriate answer to any institution (public or private).

Presentation and terms of the transaction

Medasys acquired the totality of Netika's shares from NKKD, the sole shareholder of Netika, under the following terms and conditions:

- Acquisition price: € 9.8 million;
- Guarantee of ordinary assets and liabilities to Medasys;
- Duration of the guarantee of liabilities: 3 years from this day (except in fiscal, social and customs matters for which the guarantee is unlimited);
- The transfer of ownership occurred today.

Financing

The acquisition was financed through a shareholder loan granted by Dedalus (majority shareholder) to Medasys for an amount equal to 100% of the purchase price.

The main features of the shareholder loan are as follows:

- Maturity of the current account advance in 10 years;

Dedalus Italia S.p.A. con Socio Unico Dedalus Finance GmbH**Sede Legale:**

Via di Collodi 6/c
50141 Firenze

Tel. +39 055 42471**Fax** +39 055 451660
reception@dedalus.eu**Capitale sociale:**

€ 11.634.062 i.v.
R.E.A. Firenze 591564

Codice fiscale, partita IVA
e registro imprese
05994810488



- Automatic and anticipated reimbursement in the event of a change of control;
- Interest rate of 3,5 % per annum;
- Possibility of converting the receivable in the event of a capital transaction or the issue of financial instruments.

The Group reserves the right to repay the shareholder loan in advance by mean of a capital increase, a bank loan, an issue of debt securities or by any other means.

This acquisition under the aforementioned conditions as well as the terms of its financing have been subject to prior approval by the Management Board and the Supervisory committee of Medasys.

An enriched offer adapted to the private and public sector

By integrating Netika's solutions into its portfolio, Medasys is able to address the **private sector** with a forward-thinking solution in its deployment methodology and urbanization.

To meet the demands of the hospital laboratories, Netika will complete Medasys' offer on a functional level and will enable, through its recent successes, to manage the project of public laboratories of all sizes. KaliSil will be deployed in medium-sized (and small) institutions/territories while DxLab, Medasys multi-site laboratory information system will be deployed in large institutions / territories.

"The integration of Netika within Medasys Group gives it a significant market share in the private sector and consolidates its position as a leader in the management of technical platforms as part of the implementation of Hospital networks." explained **Frederic Vaillant**, Chairman and CEO of Medasys.

Netika will also benefit from the contributions of **Dedalus Group**, the majority shareholder of Medasys whose diagnostic activity represents nearly € 45 million, notably with its middleware, its pathology solution and its clinical decision support system.

"We are glad to support **Medasys'** growth strategy – says **Giorgio Moretti**, CEO of Dedalus – With the acquisition of **Netika** the Group further strengthens its leading position in Europe in the ambits of hospital information systems and diagnostic information systems. The Group's expansion strategy is supported by the shareholder **Ardian**, the biggest Private Equity fund in Europe, which provides us a valuable help in developing the French market. Thanks to the constant investments in R&D, which allow Dedalus and Medasys to offer products more and more suited to the continuous market developments, we are able to support our customers during this strong evolution phase of the French healthcare system."

Much more than a financial transaction, this acquisition will enable Medasys to be as close as possible to the expectations of biologists. The Group's synergies will strengthen the diagnostic division. To ensure continuity of the activity, Medasys decided to create a strategic committee dedicated to the management of laboratories, in which Daniel Klumpp, founder of Netika, will ensure the vice-presidency Strategy LIS.





ABOUT MEDASYS

Medasys is a major healthcare software publisher in the areas of EMR, care production, biology and medical imaging, allowing public and private healthcare facilities to optimize and enhance reliability of medical processes within a performance, patient safety and costs reduction standpoint.

Medasys is listed in Compartment C of Euronext Paris (mnemonic MED – code ISIN FR 0000052623). It employs 200 people and is present in France (Clamart and Lyon), Belgium, Algeria, Morocco and Japan. Since July 1st of 2016, Medasys is part of Dedalus Group, one of the European leaders in Healthcare software solutions.

Beyond its business activities, Medasys is also determined to act on its internal activities thanks to an environmental policy that follows five principles: using videoconferences, following telecommuting, reducing the consumption of paper and cartridges and improving the management of our waste. Medasys has been ISO 14001 v2004 certified since December 21, 2012.

Learn more about Medasys www.medasys.com

ABOUT DEDALUS

Founded in 1990 in Florence, Dedalus, with more than 1.600 employees, of which about 600 abroad, is European leader in Healthcare software solutions, even thanks to the acquisition of Noemalife in 2016, through which it achieved further leading positions in the segment of diagnostic and clinical management solutions. In the same year, the European Private Equity Fund ARDIAN acquired 60% of the Group.

In the last five years, Dedalus accelerated its international expansion, exploiting the full functional coverage of all ICT needs of any healthcare system (not limiting to hospital systems) both public and private, thanks to an offer portfolio of over 200 solutions, developed by a R&D team of more than 600 people.

Dedalus is present worldwide in 25 Countries, with its own local companies or through Joint Ventures with the major local players. Dedalus has a leading position in many Countries and it drives important projects in Italy, France, China, South Africa, Ecuador, Peru, Chile, Mexico, Saudi Arabia, Tunisia, Spain, Romania, Bosnia, UK and USA.

Learn more about Dedalus www.dedalus.eu

Contact Medasys: Service Marketing Communication – Tel : +33(0) 1 75 60 91 00

Email: servicepresse@medasys.com

ABOUT NETIKA

Founded in 2000, Netika is one of the market leaders in medical biology laboratories with its two flagship products: KaliLab and KaliSil. With more than 2,800 healthcare institutions, Netika now wants to expand to other medical fields such as medical imaging with its KaliRad product.

Learn more about Netika www.netika.net

